Pfizer Investor Presentation — November 2021

Document content

Breakthroughs that change patients' lives ®

November 2, 2021Third Quarter 2021

Earnings TeleconferenceIntroduction

Senior Vice President,

Chief Investor Relations Officer3

Third Quarter 2021 EarningsForward -Looking Statements and Non- GAAP Financial Information

Our discussions during this conference call will include forward- looking statements that are subject to substantial risks and uncertainties that could cause actual

results to differ materially from those expressed or implied by such statements. We include forward- looking statements about, am ong other topics, our

anticipated operating and financial performance, reorganizations, business plans and prospects, expectations for our product pipeline, in -line products and

product candidates, including anticipated regulatory submissions, data read- outs, study starts, approvals, clinical trial result s and other developing data,

revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, dividends and share

repurchases, plans for and prospects of our acquisitions, dispositions and other business development activities, and our abi lity to successfully capitalize on

these opportunities, manufacturing and product supply, our efforts to respond to COVID -19, including Comirnaty and our investigational protease inhibitors, and

our expectations regarding the impact of COVID -19 on our business, operations and financial results. Among other things, statements regarding revenue and

earnings per share growth; the development or commercial potential of our product pipeline, in- line products, product candidates and additional indications,

including expected clinical trial protocols, the timing of the initiation and progress of clinical trials and data read- outs fro m trials; the timing for the submission of